TY - JOUR
T1 - Novel pathogenic variants and quantitative phenotypic analyses of Robinow syndrome
T2 - WNT signaling perturbation and phenotypic variability
AU - Zhang, Chaofan
AU - Jolly, Angad
AU - Shayota, Brian J.
AU - Mazzeu, Juliana F.
AU - Du, Haowei
AU - Dawood, Moez
AU - Soper, Patricia Celestino
AU - Ramalho de Lima, Ariadne
AU - Ferreira, Bárbara Merfort
AU - Coban-Akdemir, Zeynep
AU - White, Janson
AU - Shears, Deborah
AU - Thomson, Fraser Robert
AU - Douglas, Sarah Louise
AU - Wainwright, Andrew
AU - Bailey, Kathryn
AU - Wordsworth, Paul
AU - Oldridge, Mike
AU - Lester, Tracy
AU - Calder, Alistair D.
AU - Dumic, Katja
AU - Banka, Siddharth
AU - Donnai, Dian
AU - Jhangiani, Shalini N.
AU - Potocki, Lorraine
AU - Chung, Wendy K.
AU - Mora, Sara
AU - Northrup, Hope
AU - Ashfaq, Myla
AU - Rosenfeld, Jill A.
AU - Mason, Kati
AU - Pollack, Lynda C.
AU - McConkie-Rosell, Allyn
AU - Kelly, Wei
AU - McDonald, Marie
AU - Hauser, Natalie S.
AU - Leahy, Peter
AU - Powell, Cynthia M.
AU - Boy, Raquel
AU - Honjo, Rachel Sayuri
AU - Kok, Fernando
AU - Martelli, Lucia R.
AU - Filho, Vicente Odone
AU - Genomics England Research Consortium, England Research Consortium
AU - Muzny, Donna M.
AU - Gibbs, Richard A.
AU - Posey, Jennifer E.
AU - Liu, Pengfei
AU - Lupski, James R.
AU - Sutton, V. Reid
AU - Carvalho, Claudia M.B.
N1 - Funding Information:
The authors would like to thank the individuals and their families who contributed to this study, especially Kim Kremeier and the Robinow Syndrome Foundation for facilitating this collaboration. We would also like to thank Dr. Chad A. Shaw for helpful discussions about the quantitative methodology applied here to study HPO terms. This work was supported in part by the US National Human Genome Research Institute (NHGRI)/NHLBI grant number UM1HG006542 to the Baylor-Hopkins Center for Mendelian Genomics (BHCMG); the National Institute of Neurological Disorders and Stroke (NINDS) R35 NS105078 (J.R.L.); the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) R03 HD092569 (C.M.B.C and V.R.S.); the National Institute of General Medical Sciences (NIGMS) R01 GM132589 (C.M.B.C); NHGRI K08 HG008986 (J.E.P.); the JPB Foundation (W.K.C.); the BCM Medical Scientist Training Program and the Department of Genetics and Genomics (A.J.); the NIH T32 (GM07526-43) Medical Genetics Research Fellowship Program (B.J.S.); and the American College of Medical Genetics and Genomics Foundation for Genetics and Genomic Medicine (B.J.S.). This research was made possible through access to the data and findings generated by the 100,000 Genomes Project. The 100,000 Genomes Project is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The 100,000 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK, and the Medical Research Council have also funded research infrastructure. The 100,000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support. BCM and Miraca Holdings have formed a joint venture with shared ownership and governance of BG, which performs clinical microarray analysis (CMA), clinical ES (cES), and clinical biochemical studies. V.R.S. and P.L. receive professional services compensation from BG and J.R.L. serves on the Scientific Advisory Board of the BG. J.R.L. has stock ownership in 23andMe, is a paid consultant for the Regeneron Genetics Center, and is a coinventor on multiple United States and European patents related to molecular diagnostics for inherited neuropathies, eye diseases, and bacterial genomic fingerprinting. W.K.C. is a is a paid consultant for the Regeneron Genetics Center. P.C.S. and S.M. are employees of GeneDx. The other authors declare no competing interests.
Funding Information:
The authors would like to thank the individuals and their families who contributed to this study, especially Kim Kremeier and the Robinow Syndrome Foundation for facilitating this collaboration. We would also like to thank Dr. Chad A. Shaw for helpful discussions about the quantitative methodology applied here to study HPO terms. This work was supported in part by the US National Human Genome Research Institute (NHGRI)/ NHLBI grant number UM1HG006542 to the Baylor-Hopkins Center for Mendelian Genomics (BHCMG); the National Institute of Neurological Disorders and Stroke (NINDS) R35 NS105078 (J.R.L.); the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) R03 HD092569 (C.M.B.C and V.R.S.); the National Institute of General Medical Sciences (NIGMS) R01 GM132589 (C.M.B.C); NHGRI K08 HG008986 (J.E.P.); the JPB Foundation (W.K.C.); the BCM Medical Scientist Training Program and the Department of Genetics and Genomics (A.J.); the NIH T32 ( GM07526-43 ) Medical Genetics Research Fellowship Program (B.J.S.); and the American College of Medical Genetics and Genomics Foundation for Genetics and Genomic Medicine (B.J.S.).
Funding Information:
This research was made possible through access to the data and findings generated by the 100,000 Genomes Project. The 100,000 Genomes Project is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The 100,000 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK, and the Medical Research Council have also funded research infrastructure. The 100,000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support.
Publisher Copyright:
© 2021 The Author(s)
PY - 2022/1/13
Y1 - 2022/1/13
N2 - Robinow syndrome (RS) is a genetically heterogeneous disorder with six genes that converge on the WNT/planar cell polarity (PCP) signaling pathway implicated (DVL1, DVL3, FZD2, NXN, ROR2, and WNT5A). RS is characterized by skeletal dysplasia and distinctive facial and physical characteristics. To further explore the genetic heterogeneity, paralog contribution, and phenotypic variability of RS, we investigated a cohort of 22 individuals clinically diagnosed with RS from 18 unrelated families. Pathogenic or likely pathogenic variants in genes associated with RS or RS phenocopies were identified in all 22 individuals, including the first variant to be reported in DVL2. We retrospectively collected medical records of 16 individuals from this cohort and extracted clinical descriptions from 52 previously published cases. We performed Human Phenotype Ontology (HPO) based quantitative phenotypic analyses to dissect allele-specific phenotypic differences. Individuals with FZD2 variants clustered into two groups with demonstrable phenotypic differences between those with missense and truncating alleles. Probands with biallelic NXN variants clustered together with the majority of probands carrying DVL1, DVL2, and DVL3 variants, demonstrating no phenotypic distinction between the NXN-autosomal recessive and dominant forms of RS. While phenotypically similar diseases on the RS differential matched through HPO analysis, clustering using phenotype similarity score placed RS-associated phenotypes in a unique cluster containing WNT5A, FZD2, and ROR2 apart from non-RS-associated paralogs. Through human phenotype analyses of this RS cohort and OMIM clinical synopses of Mendelian disease, this study begins to tease apart specific biologic roles for non-canonical WNT-pathway proteins.
AB - Robinow syndrome (RS) is a genetically heterogeneous disorder with six genes that converge on the WNT/planar cell polarity (PCP) signaling pathway implicated (DVL1, DVL3, FZD2, NXN, ROR2, and WNT5A). RS is characterized by skeletal dysplasia and distinctive facial and physical characteristics. To further explore the genetic heterogeneity, paralog contribution, and phenotypic variability of RS, we investigated a cohort of 22 individuals clinically diagnosed with RS from 18 unrelated families. Pathogenic or likely pathogenic variants in genes associated with RS or RS phenocopies were identified in all 22 individuals, including the first variant to be reported in DVL2. We retrospectively collected medical records of 16 individuals from this cohort and extracted clinical descriptions from 52 previously published cases. We performed Human Phenotype Ontology (HPO) based quantitative phenotypic analyses to dissect allele-specific phenotypic differences. Individuals with FZD2 variants clustered into two groups with demonstrable phenotypic differences between those with missense and truncating alleles. Probands with biallelic NXN variants clustered together with the majority of probands carrying DVL1, DVL2, and DVL3 variants, demonstrating no phenotypic distinction between the NXN-autosomal recessive and dominant forms of RS. While phenotypically similar diseases on the RS differential matched through HPO analysis, clustering using phenotype similarity score placed RS-associated phenotypes in a unique cluster containing WNT5A, FZD2, and ROR2 apart from non-RS-associated paralogs. Through human phenotype analyses of this RS cohort and OMIM clinical synopses of Mendelian disease, this study begins to tease apart specific biologic roles for non-canonical WNT-pathway proteins.
KW - DVL2
KW - HPO terms
KW - genotype-phenotype correlation
KW - indel mutations
KW - molecular diagnosis
KW - quantitative phenotyping cluster heatmap
KW - screw-tail breed dogs
KW - skeletal dysplasia
KW - traits and OMIM clinical synopsis
UR - http://www.scopus.com/inward/record.url?scp=85121375364&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121375364&partnerID=8YFLogxK
U2 - 10.1016/j.xhgg.2021.100074
DO - 10.1016/j.xhgg.2021.100074
M3 - Article
C2 - 35047859
AN - SCOPUS:85121375364
SN - 2666-2477
VL - 3
JO - Human Genetics and Genomics Advances
JF - Human Genetics and Genomics Advances
IS - 1
M1 - 100074
ER -